Lunai Bioworks, Inc. (NASDAQ: LNAI) has taken legal action against alleged naked short sellers, filing a federal securities fraud lawsuit in Delaware. The company, represented by national law firms Dickinson Wright and Fox Rothschild, accuses unidentified entities of orchestrating a coordinated scheme to manipulate trading in Lunai's common stock. The complaint alleges repeated violations of SEC Regulation SHO, including failures to deliver shares that reached as high as 234.6 times the maximum baseline daily rate. During certain periods, failures to deliver allegedly represented 81.6% of the company's total outstanding shares.
According to the complaint, trading activity purportedly exceeded Lunai's available share count on multiple occasions. On March 17, 2026, more than 554 million shares were traded, representing 15.3 times the company's outstanding shares. Similarly, on May 4, 2026, over 100 million shares changed hands. These figures suggest that short sellers may have sold shares they did not possess or could not borrow, a practice known as naked short selling. Such activity can artificially depress a stock's price, harming the company and its shareholders.
The lawsuit seeks compensatory and special damages, injunctive relief, and recovery of legal costs. Counsel for Lunai indicated they intend to pursue expedited discovery to identify the unnamed defendants and seek emergency relief to halt any ongoing manipulative trading. This case highlights the ongoing challenges publicly traded companies face from abusive short-selling practices that undermine market integrity.
Lunai Bioworks is an AI-driven platform for precision medicine, headquartered in Sacramento, California. The company focuses on identifying targets for new therapeutics and biodefense countermeasures. Its technologies include a cancer immunotherapy for solid tumors and proprietary platforms that transform complex biomedical data into predictive insights. Lunai's platforms, such as Augusta, an AI-powered precision neurology platform, target central nervous system disorders. The company also pursues federal government contracts supporting national security and biodefense applications.
For the broader market, this lawsuit underscores the regulatory and legal risks associated with naked short selling. If successful, it could set a precedent for other companies experiencing similar trading anomalies. The involvement of major law firms like Fox Rothschild and Dickinson Wright signals the severity of the allegations. Fox Rothschild, with approximately 1,000 attorneys across 30 offices, brings extensive experience in securities litigation. Dickinson Wright, with over 500 attorneys in 23 offices, also has a strong securities practice.
This legal action may lead to increased scrutiny of short-selling activities and potentially spur regulatory reforms. For investors, the case highlights the importance of monitoring trading volumes and fail-to-deliver data as indicators of potential manipulation. The outcome could impact how companies respond to perceived market abuse and may influence future litigation strategies.
